EGFR triple mutation inhibitors and their applications
By developing a new structure of EGFR inhibitory compounds, the problem of the existing technology being difficult to inhibit the tri-mutation of EGFR 19del/T790M/C797S has been solved, effective treatment of EGFR-related diseases has been achieved, and drug resistance has been overcome.
Patent Information
- Application Number
- CN201910315199.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2019-04-18
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing EGFR inhibitors are difficult to effectively inhibit the EGFR 19del/T790M/C797S tri-mutation, leading to drug resistance problems and affecting the therapeutic effect.
A series of new structural EGFR inhibitory compounds have been developed to bind to the EGFR tyrosine kinase domain through specific molecular structures, significantly inhibiting the EGFR 19del/T790M/C797S tri-mutation, as a new generation of EGFR inhibitors.
These compounds can significantly inhibit the tri-mutation of EGFR 19del/T790M/C797S, providing new drug options for the treatment of EGFR-related diseases, and overcoming drug resistance issues in existing treatment options.
Smart Images

Figure CN111825658B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medicinal chemistry; specifically, the present invention relates to novel indole and trisubstituted imidazole compounds as EGFR triple mutation inhibitors and their use as EGFR inhibitors in the preparation of drugs for tumor-related diseases. Background Art
[0002] Epidermal growth factor receptor (EGFR) is a type of transmembrane glycoprotein present on the cell membrane of human tissues, with a molecular weight of 170-kDa. It belongs to the ErbB receptor tyrosine kinase (RTK) family together with ErbB-2 (HER2 / Neu), ErbB-3 (HER3), and ErbB-4 (HER4). These receptors are composed of an extracellular ligand-binding domain, which is then connected to the intracellular tyrosine kinase through the transmembrane region. The tyrosine kinase domain in the ErbB receptor is highly conserved, while the extracellular domain has significant differences, which also causes the receptor to show different specificities when binding to ligands. EGFR and ErbB-4 have complete extracellular ligand-binding domains and activatable kinase domains, while the extracellular domain of ErbB-2 may not have ligand binding ability. Although ErbB-3 can bind to ATP, it is an inactive tyrosine kinase receptor, and its homodimer is inactive. The signal transduction mode of EGFR is mainly to bind to specific ligands, causing dimerization, activating its intracellular tyrosine kinase activity, causing autophosphorylation of some terminal tyrosine residues, and thus activating downstream signaling pathways.
[0003] Studies have found that epidermal growth factor receptor plays an important role in cell proliferation and metabolism. Since it is overexpressed in many cancer cells, it is of great research significance to use EGFR as a drug target. At present, tumor molecular targeted drugs for EGFR are mainly divided into two categories according to their properties: one is monoclonal antibodies that directly act on the extracellular receptor region; the other is small molecule inhibitors that interfere with the activity of EGFR tyrosine kinase in cells. Monoclonal antibody drugs act on the extracellular ligand binding domain of EGFR, making it impossible for endogenous ligands such as EGF to bind to EGFR, thereby preventing the signal from entering the cell; small molecule drugs bind to the intracellular tyrosine kinase catalytic region to inhibit its catalytic activity, thereby blocking cell proliferation signals.
[0004] EGFR mutations are mainly concentrated in exons 18-21, which are responsible for encoding the EGFR tyrosine kinase domain. Among them, exon 19 deletion accounts for 44% of EGFR tyrosine kinase sensitive mutations. The point mutation in exon 21, L858R mutation, accounts for 41% of EGFR tyrosine kinase sensitive mutations. Mutations from glycine to serine, alanine or cysteine at residue 719 account for 10% of the total mutations, while insertion or duplication mutations in exon 20 account for the remaining 5%. Among them, exon 19 deletion and L858R point mutation are the most common sensitive mutations. These mutations enhance the activity of EGFR kinase, thereby enhancing downstream signaling pathways. In addition, it has been reported that 50% of patients with resistance to EGFR tyrosine kinase inhibitor treatment have T790M point mutations on exon 20. This mutation is believed to be generated during treatment because it has not been detected in untreated patients. A series of small molecule inhibitors have been derived for these different mutations.
[0005] First, there are the first generation of EGFR small molecule inhibitors, such as Gefitinib and Erlotinib. These inhibitors mainly target sensitive mutations, but with the discovery of the T790M resistance mutation, patients gradually develop drug resistance. Therefore, the second and third generation EGFR inhibitors were derived. This type of inhibitor mainly enhances the inhibitory activity by covalently binding the Michael receptor on the molecule to the cysteine 797 residue of the protein.
[0006] Although there is hope for the use of third-generation EGFR inhibitors to treat non-small cell lung cancer patients with T790M mutations, drug resistance is gradually developing. Studies have found that drug resistance is mainly due to the mutation of Cys797 residues to Ser797 residues, which destroys the binding force between small molecules and kinases, causing the third-generation inhibitors to basically lose their effectiveness.
[0007] Therefore, there is an urgent need in the art to develop a new generation of inhibitors to overcome the EGFR L858R / T790M / C797S and EGFR 19del / T790M / C797S triple mutations. Summary of the invention
[0008] The purpose of the present invention is to provide a novel EGFR inhibitory compound, which can inhibit the EGFR19del / T790M / C797S triple mutation.
[0009] Another object of the present invention is to provide a pharmaceutical composition comprising the above compound.
[0010] Another object of the present invention is to provide the use of the above compounds in the preparation of drugs for treating EGFR-related diseases or inhibiting EGFR.
[0011] In the first aspect, the present invention provides a compound represented by the general formula I or a stereoisomer or optical isomer thereof or a pharmaceutically acceptable salt thereof:
[0012]
[0013] In the formula,
[0014] W is CH or N;
[0015] X is CH or N;
[0016] Y is CH or N or C halogen;
[0017] Z is CH or N;
[0018] R 1 The number of is any integer from 1 to 5, optionally located at 1', 2', 5', 6' or 7', and independently selected from: H, halogen, C1-C6 substituted or unsubstituted alkyl,
[0019]
[0020] Wherein, n is an integer from 0 to 4;
[0021] P is 1-2 C1-C3 alkyl groups or does not exist;
[0022] Q is -OH, -SH, -NH2, -NHCH3, -COOH, -CONH2, -NHCONH2, -NHCONHNH2, -SO3H, -SO2NH2;
[0023] When R 4 for When R 4 Each position can have one or more Qs;
[0024] X is O, S, or NH;
[0025] R 2 Selected from: hydrogen, C1-C5 substituted or unsubstituted alkylcarboxamide, C2-C5 substituted or unsubstituted alkenylcarboxamide;
[0026] R 3 Selected from: hydrogen, halogen, NR 7 R 8 , substituted N-C1-C3 alkylpiperazinyl;
[0027] R 7 and R 8 Independently selected from: H, C1-C6 substituted or unsubstituted alkyl, NR 9 R 10 ;
[0028] R 9 and R 10 Independently selected from: H, C1-C3 substituted or unsubstituted alkyl.
[0029] In a specific embodiment,
[0030] W is CH;
[0031] X is CH or N;
[0032] Y is CH or N;
[0033] Z is CH;
[0034] R 1 The number of is 1 or 2, optionally located at the 1' or 5' position, and independently selected from: H, C1-C6 substituted or unsubstituted alkylhydroxy or polyhydroxy, halogen;
[0035] R 2 Selected from: hydrogen, C1-C3 substituted or unsubstituted alkylcarboxamide, C2-C3 substituted or unsubstituted alkenylcarboxamide;
[0036] R 3 Selected from: Halogen, NR 7 R 8 ;
[0037] R 7 and R 8 Independently selected from: H, C1-C3 substituted or unsubstituted alkyl, NR 9 R 10 ;
[0038] R 9 and R 10 Independently selected from: H, C1-C3 substituted or unsubstituted alkyl.
[0039] In a specific embodiment, the present invention provides the following compounds or their stereoisomers or optical isomers or pharmaceutically acceptable salts:
[0040]
[0041] In a second aspect, the present invention provides a compound represented by general formula II or a stereoisomer or optical isomer thereof or a pharmaceutically acceptable salt thereof:
[0042]
[0043] In the formula,
[0044] R 1 Selected from:
[0045]
[0046] Wherein, n is an integer from 0 to 4;
[0047] P is 1-2 C1-C3 alkyl groups or does not exist;
[0048] Q is -OH, -SH, -NH2, -NHCH3, -COOH, -CONH2, -NHCONH2, -NHCONHNH2, -SO3H, -SO2NH2;
[0049] When R 4 for When R 4 Each position can have one or more Qs;
[0050] X is O, S, or NH;
[0051] R 4 Selected from:
[0052] The number of A is any integer from 0 to 4, and is independently selected from: halogen, substituted or unsubstituted C1-C3 alkoxy;
[0053] The number of V, S, and T is any integer from 0 to 4, and is independently selected from halogen, substituted or unsubstituted C1-C3 alkoxy;
[0054] R 5 Selected from: H, substituted or unsubstituted
[0055] R 6 Selected from: H, substituted or unsubstituted C1-C3 alkyl.
[0056] In a specific embodiment,
[0057] R 4 Selected from:
[0058] The number of A is any integer from 0 to 4, and is independently selected from: halogen, substituted or unsubstituted C1-C3 alkoxy;
[0059] The number of V is any integer from 0 to 4, and is independently selected from halogen, substituted or unsubstituted C1-C3 alkoxy;
[0060] R 5 Selected from: substituted or unsubstituted
[0061] R 6 Selected from: H.
[0062] In a specific embodiment, the present invention provides a compound selected from the following or a stereoisomer or optical isomer or a pharmaceutically acceptable salt thereof:
[0063]
[0064] In a third aspect, the present invention provides a pharmaceutical composition comprising the compound described in the first or second aspect or its stereoisomer or optical isomer or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier or excipient.
[0065] In a preferred embodiment, the pharmaceutical composition is in a dosage form suitable for oral administration, including but not limited to tablets, solutions, suspensions, capsules, granules, and powders.
[0066] In a fourth aspect, the present invention provides use of the compound described in the first or second aspect or its stereoisomer or optical isomer or pharmaceutically acceptable salt, or the pharmaceutical composition described in the third aspect in the preparation of a drug for treating or preventing EGFR-mediated diseases or inhibiting EGFR.
[0067] In a specific embodiment, the EGFR-mediated disease is cancer.
[0068] In a specific embodiment, the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, breast cancer, prostate cancer, glioma, ovarian cancer, head and neck squamous cell carcinoma, cervical cancer, esophageal cancer, liver cancer, kidney cancer, pancreatic cancer, colon cancer, skin cancer, leukemia, lymphoma, gastric cancer, multiple myeloma and solid tumors.
[0069] In a fifth aspect, the present invention provides a method for treating or preventing EGFR-mediated diseases, comprising administering the compound described in the first or second aspect or the pharmaceutical composition described in the third aspect to a subject in need thereof.
[0070] In a preferred embodiment, the EGFR-mediated disease is cancer; preferably, the cancer is selected from the group consisting of non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, breast cancer, prostate cancer, glioma, ovarian cancer, head and neck squamous cell carcinoma, cervical cancer, esophageal cancer, liver cancer, kidney cancer, pancreatic cancer, colon cancer, skin cancer, leukemia, lymphoma, gastric cancer, multiple myeloma and solid tumors.
[0071] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. DETAILED DESCRIPTION
[0072] After extensive and in-depth research, the inventor unexpectedly discovered a series of EGFR inhibitory compounds with new structures, which can significantly inhibit the EGFR 19del / T790M / C797S triple mutation, thereby being able to develop a new generation of EGFR inhibitors and laying a new material foundation for the development of a new generation of EGFR inhibitors. On this basis, the present invention was completed.
[0073] Definition of terms
[0074] Some of the groups involved in this article are defined as follows:
[0075] Herein, "alkyl" refers to a saturated branched or straight chain alkyl group having a carbon chain length of 1 to 10 carbon atoms, and preferred alkyl groups include alkyl groups having 2 to 8, 1 to 6, 1 to 4, 3 to 8, 1 to 3 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, heptyl, etc. The alkyl group may be substituted with one or more substituents, such as halogen or haloalkyl. For example, the alkyl group may be an alkyl group substituted with 1 to 4 fluorine atoms, or the alkyl group may be an alkyl group substituted with a fluoroalkyl group.
[0076] Herein, "alkoxy" refers to an oxy group substituted by an alkyl group. Preferred alkoxy groups are alkoxy groups with a length of 1 to 6 carbon atoms, more preferably alkoxy groups with a length of 1 to 4 carbon atoms. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, and the like.
[0077] As used herein, "halogen" refers to fluorine, chlorine, bromine and iodine.
[0078] As used herein, "acylamino" refers to a group having the structural formula "-R'-NH-C(O)-R", wherein R' can be selected from hydrogen or alkyl, and R can be selected from alkyl, alkenyl, alkynyl, NR c R d Alkyl substituted, NR c R d Substituted alkenyl and NR c R d substituted alkynyl, alkyl substituted by halogen, alkenyl substituted by cyano, wherein R c and R d It may be selected from alkyl and alkenyl groups.
[0079] Herein, "substituted or unsubstituted" or "optionally substituted" means that the substituent it modifies can be optionally substituted by 1-5 (e.g., 1, 2, 3, 4 or 5) substituents selected from the following: halogen, C 1-4 Aldehyde, C 1-6Straight-chain or branched alkyl, cyano, nitro, amino, hydroxy, hydroxymethyl, halogen-substituted alkyl (e.g., trifluoromethyl), halogen-substituted alkoxy (e.g., trifluoromethoxy), carboxyl, C 1-4 Alkoxy, ethoxycarbonyl, N(CH3) and C 1-4 Acyl.
[0080] The term "substituted" as used herein means that one or more hydrogen atoms on a specific group are replaced by a specific substituent. The specific substituent may be a substituent described above or a specific substituent appearing in each embodiment. Therefore, in the present invention, the substituents in the general formula may each independently be a corresponding group in the specific compound in the embodiment; that is, the present invention includes a combination of the substituents in the above general formula, and also includes a combination of some of the substituents shown in the general formula and other specific substituents appearing in the embodiment.
[0081] Compounds of the present invention
[0082] The present invention provides a series of EGFR inhibitory compounds with novel structures, which can significantly inhibit the EGFR 19del / T790M / C797S triple mutation. In a specific embodiment, the present invention provides a compound represented by general formula I or II or a stereoisomer or optical isomer or a pharmaceutically acceptable salt thereof:
[0083]
[0084] In the formula, each substituent is as defined above.
[0085] On the basis of the compound of the present invention, those skilled in the art can make it into a pharmaceutically acceptable salt. For example, the compound of the present invention can be reacted with an inorganic acid or an organic acid to form a conventional pharmaceutically acceptable salt. The inorganic acid includes hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, aminosulfonic acid and phosphoric acid, and the organic acid includes citric acid, tartaric acid, lactic acid, pyruvic acid, acetic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid, ethanesulfonic acid, naphthalene disulfonic acid, maleic acid, malic acid, malonic acid, fumaric acid, succinic acid, propionic acid, oxalic acid, trifluoroacetic acid, stearic acid, pamoic acid, hydroxymaleic acid, phenylacetic acid, benzoic acid, salicylic acid, glutamic acid, ascorbic acid, p-aminobenzenesulfonic acid, 2-acetoxybenzoic acid and isethionic acid, etc.; or the compound of the present invention is reacted with an inorganic base to form a sodium salt, potassium salt, calcium salt, aluminum salt or ammonium salt; or with an organic base to form a methylamine salt, ethylamine salt or ethanolamine salt.
[0086] Unless otherwise specified, the structural formulas described in the present invention are intended to include all isomeric forms (such as enantiomers, diastereomers and geometric isomers (or conformational isomers): for example, R, S configurations containing asymmetric centers, (Z), (E) isomers of double bonds, etc. Therefore, single stereochemical isomers of the compounds of the present invention or mixtures of their enantiomers, diastereomers or geometric isomers (or conformational isomers) are all within the scope of the present invention.
[0087] Pharmaceutical compositions and administration methods of the present invention
[0088] The compounds of the present invention can be used to prepare drugs for treating diseases mediated by EGFR (especially EGFR 19del / T790M / C797S triple mutation), such as cancer, including but not limited to: non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, breast cancer, prostate cancer, glioma, ovarian cancer, head and neck squamous cell carcinoma, cervical cancer, esophageal cancer, liver cancer, kidney cancer, pancreatic cancer, colon cancer, skin cancer, leukemia, lymphoma, gastric cancer, multiple myeloma and solid tumors.
[0089] In view of this, based on the compounds of the present invention and pharmaceutically acceptable salts thereof, the present invention also provides a pharmaceutical composition comprising the compounds of the present invention, wherein the pharmaceutical composition optionally comprises a pharmaceutically acceptable excipient.
[0090] In a specific embodiment, the pharmaceutical composition of the present invention comprises a safe and effective amount of the compound of the present invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier. Wherein "safe and effective amount" means: the amount of the compound is sufficient to significantly improve the condition without causing serious side effects.
[0091] "Pharmaceutically acceptable excipients or carriers" refer to: one or more compatible solid or liquid fillers or gel substances, which are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with the compounds of the present invention and with each other without significantly reducing the efficacy of the compounds. Some examples of pharmaceutically acceptable carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers Wetting agents (such as sodium lauryl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.
[0092] There is no particular limitation on the administration of the compound or pharmaceutical composition of the present invention. Representative administrations include, but are not limited to, oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous), and topical administration.
[0093] Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) fillers or extenders, for example, starches, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, for example, hydroxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose, and acacia; (c) humectants, for example, glycerol; (d) disintegrants, for example, agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizers, for example, paraffin; (f) absorption accelerators, for example, quaternary ammonium compounds; (g) wetting agents, for example, cetyl alcohol and glyceryl monostearate; (h) adsorbents, for example, kaolin; and (i) lubricants, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, or mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
[0094] Solid dosage forms such as tablets, pills, capsules, pills and granules can be prepared using coatings and shell materials, such as enteric coatings and other materials known in the art. They may contain opacifiers, and the release of the active compound or compounds in such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can also be formed into microencapsulated form with one or more of the above-mentioned excipients.
[0095] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures. In addition to the active compound, the liquid dosage form may contain an inert diluent conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butylene glycol, dimethylformamide and oils, in particular cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil or mixtures of these substances.
[0096] Besides these inert diluents, the composition may also include adjuvants such as wetting agents, emulsifying and suspending agents, sweeteners, flavoring agents, and perfumes.
[0097] Suspensions, in addition to the active compounds, may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methanol and agar, or mixtures of these substances.
[0098] Compositions for parenteral injection may include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
[0099] Dosage forms for topical administration of the compounds of the invention include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be required.
[0100] The compounds of the present invention can be administered alone or in combination with other pharmaceutically acceptable compounds. When using a pharmaceutical composition, a safe and effective amount of the compounds of the present invention is applied to a mammal (such as a human) in need of treatment, wherein the dosage during administration is a pharmaceutically effective dosage. The compounds and pharmaceutical compositions of the present invention can be administered via the oral, nasal, skin, lung or gastrointestinal tract. Oral administration, either once or in divided doses, is most preferred. Regardless of the method of administration, the optimal dose for an individual should be determined based on the specific treatment. Usually, the dose is started with a small dose and gradually increased until the most suitable dose is found. Of course, the specific dose should also take into account factors such as the route of administration and the patient's health status, which are all within the skill range of skilled physicians.
[0101] Advantages of the present invention:
[0102] 1. The compound of the present invention is a novel EGFR inhibitory compound; and
[0103] 2. The compounds of the present invention can significantly inhibit the EGFR 19del / T790M / C797S triple mutation, thereby being able to be developed as a new generation of EGFR inhibitors and laying a new material foundation for the development of a new generation of EGFR inhibitors.
[0104] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended only to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods for the unrecorded specific conditions in the following examples are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and weight parts.
[0105] Example
[0106] Material
[0107] Unless otherwise specified, the experimental materials and reagents used in the following examples can be obtained from commercial channels.
[0108] Preparation method
[0109] The preparation method of the compound of the present invention can be a conventional method in the art, or can adopt the synthesis route of the present invention.
[0110] Synthesis scheme of indole compounds
[0111]
[0112] The reaction reagents and conditions of each step are as follows:
[0113] (a) DMSO, KOH, 25℃, 1h, 3-chloropropan-1-ol, 8h, 36%;
[0114] (b) DCE, AlCl3, 0℃, 2,4-dichloropyrimidine, 55℃, 1.5h, 31%;
[0115] (c) TsOH, 2-pentanol, 4-fluoro-2-methoxy-5-nitroaniline, 105°C, 2.5h, 76%;
[0116] (d) Fe, MeOH / DCM, AcOH, 55℃, 4h;
[0117] (e) acryloyl chloride, DCM, DIPEA, 0℃, 1.5h, 35%;
[0118] (f)N,N,N-trimethylethane-1,2-diamine,DMF,K2CO3,110℃,3h,60%;
[0119] (g) Pd / C, H2, MeOH, 25℃, 5h.
[0120] Example 1: Synthesis of Compound 1
[0121] Synthesis of 3-(1H-indol-1-yl)propan-1-ol (2b) (Step a)
[0122]
[0123] Potassium hydroxide (4.48 g, 80.0 mmol) was weighed into a 250 mL single-mouth bottle, 100 mL of dimethyl sulfoxide was added, and the mixture was stirred at room temperature for 15 min. 2a (4.46 g, 40.0 mmol) was added, and the mixture was reacted at room temperature for 1 h. 3-Chloro-1-propanol (5.67 g, 60.0 mmol) was added dropwise to the solution, and the mixture was reacted at room temperature under TLC monitoring for 8 h. After the reaction was completed, a large amount of water was added to quench the mixture, and the mixture was extracted with ethyl acetate. The organic phase was collected, dried over anhydrous sodium sulfate, and the solvent was spin-dried. The crude product was separated by silica gel column chromatography with petroleum ether:ethyl acetate = 20:1 to obtain 2c, 2.59 g of a yellow liquid, with a yield of 36%.
[0124] 1 H NMR (400MHz, Chloroform-d): δ7.55(d,J=7.9Hz,1H),7.29(d,J=8.2Hz,1H),7.16–7.09(m,1H),7.06–6.97(m,2H),6.41( d,J=3.1Hz,1H),4.17(t,J=6.7Hz,2H),3.47(t,J=6.0Hz,2H),1.94(p,J=6.3Hz,2H),1.59(s,1H).LC-MS:m / z:176.2(M+H) + .
[0125] Synthesis of 3-(3-(2-chloropyrimidin-4-yl)-1H-indol-1-yl)propan-1-ol (2c) (step b)
[0126]
[0127] 2b (2.59 g, 14.7 mmol) was dissolved in 50 mL of 1,2-dichloroethane, and the mixture was cooled to 0°C in an ice bath. Anhydrous aluminum chloride (2.81 g, 21.0 mmol) was added. After 10 min, the mixture was heated to room temperature and stirred for 15 min. 2,4-dichloropyrimidine (1.73 g, 11.0 mmol) was added. The mixture was heated to 55°C and reacted for 1.5 h. After TLC monitoring, the reaction was completed and the mixture was allowed to stand and cool to room temperature. Methanol / water (20 mL / 10 mL) was then added in an ice bath. The mixture was returned to room temperature and stirred for 30 min. The filtrate was collected by suction and extracted with dichloromethane. The mixture was dried over anhydrous sodium sulfate. The solvent was spin-dried and separated by silica gel column chromatography with petroleum ether:ethyl acetate = 20:1 to obtain 1.05 g of 2c as a light yellow solid with a yield of 31%.
[0128] 1H NMR (400MHz, Chloroform-d): δ8.30(d,J=5.4Hz,1H),8.26–8.19(m,1H),7.92(s,1H),7.45–7.31(m,2H),7. 27–7.19(m,2H),4.27(t,J=6.7Hz,2H),3.54(t,J=5.7Hz,2H),2.02(p,J=6.3Hz,2H).LC-MS:m / z:288.1(M+H) + .
[0129] Synthesis of 3-(3-(2-((4-fluoro-2-methoxy-5-nitrophenyl)amino)pyrimidin-4-yl)-1H-indol-1-yl)propan-1-ol (2e) (Step c)
[0130]
[0131] 4-Methylbenzenesulfonic acid hydrate (0.75 g, 4.3 mmol) was added to a 25 mL 2-pentanol solution containing 2c (1.05 g, 3.6 mmol) and 4-fluoro-2-methoxy-5-nitroaniline (0.75 g, 4.0 mmol) at one time. The resulting mixture was stirred at 105 ° C for 2.5 h. TLC monitoring was performed to terminate the reaction and the mixture was cooled to room temperature. The filter cake was filtered and washed with ice 2-pentanol, and the filter cake was collected and vacuum dried to obtain 2d as a yellow solid (1.225 g) with a yield of 76%.
[0132] 1 H NMR (400MHz, DMSO-d6): δ10.21(s,1H),8.83(s,1H),8.73(d,J=8.2Hz,1H),8.37(d ,J=6.6Hz,1H),8.16(s,1H),7.65(d,J=8.3Hz,1H),7.58–7.48(m,2H),7.30(t,J=7 .4Hz,1H),7.11(q,J=7.5,6.8Hz,1H),4.37(t,J=7.0Hz,2H),4.00(s,3H),3.43(t, J=6.0Hz,2H),2.52(p,J=1.9Hz,1H),2.00(p,J=6.5Hz,2H).LC-MS:m / z:438.2(M+H) + .
[0133] Synthesis of 3-(3-(2-((5-amino-4-fluoro-2-methoxyphenyl)amino)pyrimidin-4-yl)-1H-indol-1-yl)propan-1-ol (2f) (Step d)
[0134]
[0135] Dissolve 2d (600.00 mg, 1.4 mmol) in 40 mL of a mixed solvent (dichloromethane: methanol = 3:1), add iron powder (2.92 g, 52.1 mmol) and 12 mL of glacial acetic acid, stir, and react at 55 ° C for 4 h. Monitor by TLC, the reaction is complete, filter, concentrate the filtrate to dryness, add saturated sodium bicarbonate solution to the residue to adjust the pH to alkaline. Extract with ethyl acetate, collect the organic phase and dry it with anhydrous sodium sulfate, spin dry the solvent, and use it directly in the next step.
[0136] Synthesis of N-(2-fluoro-5-((4-(1-(3-hydroxypropyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)acrylamide (1) (Step e)
[0137]
[0138] Acryloyl chloride (128.00 mg, 1.4 mmol) dissolved in 3.5 mL of dichloromethane was added dropwise to a solution of 2e (500.00 mg, 1.2 mmol) and N, N-diisopropylethylamine (0.24 mL, 1.4 mmol) dissolved in 16 mL of dichloromethane and cooled in an ice-water bath. The mixture was stirred for 1.5 h, monitored by TLC, and the reaction was terminated, diluted with a small amount of dichloromethane and washed with saturated sodium bicarbonate aqueous solution. The organic phase was collected, and the aqueous layer was extracted again with dichloromethane, the organic phases were combined and dried over anhydrous sodium sulfate, and the solvent was spin-dried for silica gel column chromatography, separated with dichloromethane: methanol = 200: 1 to obtain 200 mg of compound 1 as a yellow solid, with a yield of 35%.
[0139] 1 H NMR (400MHz, DMSO-d6): δ9.88(s,1H),8.61(d,J=8.5Hz,1H),8.47(s,1H),8.32(dd,J=8.7 ,6.5Hz,2H),8.09(s,1H),7.56(d,J=8.2Hz,1H),7.31–7.18(m,2H),7.18–7.07(m,2H),6.5 9(dd,J=17.0,10.2Hz,1H),6.26(dd,J=17.1,2.0Hz,1H),5.76(dd,J=10.2,2.0Hz,1H),4.6 9(s,1H),4.33(t,J=7.0Hz,2H),3.87(s,3H),3.40(t,J=6.2Hz,2H),1.96(p,J=6.6Hz,2H). 13C NMR (151MHz, DMSO): δ163.79,162.58,160.30,151.53,149.93,148.22,137.47,133.06,132.01,127.26,125.97,125.04,12 2.59,122.39,121.39,118.59,117.76,113.01,110.99,107.87,100.23,58.19,56.85,43.56,33.24.HRMS(EI)(m / z):calcd for C 25 H 24 FN5O3[M] + 461.1863, found 461.1862.
[0140] Example 2: Synthesis of N-(2-fluoro-5-((4-(1-(3-hydroxypropyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)propanamide (2) (Step e)
[0141]
[0142] Compound 2 was obtained by referring to the synthetic route of compound 1. Pale yellow solid, yield was 23%.
[0143] 1 H NMR (400MHz, DMSO-d6): δ9.54(s,1H),8.49(d,J=8.6Hz,1H),8.46(s,1H),8.35(d,J=8.0Hz ,1H),8.31(d,J=5.4Hz,1H),8.00(s,1H),7.57(d,J=8.2Hz,1H),7.27–7.21(m,2H),7.19–7. 13(m,1H),7.08(d,J=12.2Hz,1H),4.70(t,J=4.9Hz,1H),4.34(t,J=7.0Hz,2H),3.86(s,3H) ,3.42(q,J=5.8Hz,2H),2.37(q,J=7.5Hz,2H),1.97(p,J=6.5Hz,2H),1.08(t,J=7.6Hz,3H). 13C NMR (151MHz, DMSO-d6): δ172.49,162.45,160.50,157.76,151.61,150.02,147.90,137.45,132.90,126.00,125.07,122.56 ,121.31,118.90,118.12,113.02,110.97,107.84,100.13,58.20,56.81,43.53,33.25,29.28,10.19.HRMS(EI)(m / z):calcd for C 25 H 24 FN5O3[M] + 463.2020, found 463.2021.
[0144] Synthesis of 3-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5-nitrophenyl)amino)pyrimidin-4-yl)-1H-indol-1-yl)propan-1-ol (2i)
[0145]
[0146] N,N,N'-trimethylethylenediamine (35.00 mg, 0.3 mmol), N,N-diisopropylethylamine (46.00 mg, 0.3 mmol) and 2.5 mL of N,N-dimethylacetamide were sequentially placed into a 10 mL single-mouth bottle and reacted at 25 °C for 0.5 h. Then 2d (108.00 mg, 0.6 mmol) was added and the temperature was raised to 85 °C for 3 h. The reaction was stopped and allowed to stand at room temperature. Saturated brine and ethyl acetate were added for extraction. The organic phase was collected and dried over anhydrous sodium sulfate, filtered, and the filtrate was spin-dried and purified by silica gel column chromatography. The mixture was separated by dichloromethane:methanol=20:1 to obtain 84 mg of 2i as a yellow-red solid in a yield of 65%.
[0147] 1 H NMR(400MHz,Chloroform-d):9.50(s,1H),9.00(s,1H),8.30(d,J=5.2Hz,1H),8 .03–7.94(m,1H),7.67(s,1H),7.41–7.33(m,1H),7.19(dq,J=8.0,5.3Hz,3H),6 .71(s,1H),4.54(t,J=5.8Hz,2H),3.73(s,3H),3.51(t,J=5.2Hz,2H),2.95–2.8 8(m,2H),2.62(s,3H),2.43(q,J=7.7Hz,2H),2.32(s,6H),2.00(p,J=5.2Hz,2H).
[0148] Example 3: Synthesis of N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-((4-(1-(3-hydroxypropyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)propanamide (3)
[0149]
[0150] Light orange solid, yield 26%.
[0151] 1 H NMR (400MHz, Chloroform-d): δ9.84(s,1H),9.50(s,1H),9.00(s,1H),8.30(d,J=5.2Hz,1H) ,8.03–7.94(m,1H),7.67(s,1H),7.41–7.33(m,1H),7.19(dq,J=8.0,5.3Hz,3H),6.67(s,1H) ,4.44(t,J=5.8Hz,2H),3.79(s,3H),3.48(t,J=5.2Hz,2H),2.95–2.88(m,2H),2.59(s,3H),2 .49(q,J=7.7Hz,2H),2.38(s,2H),2.29(s,6H),2.00(p,J=5.2Hz,2H),1.28(t,J=7.6Hz,3H). 13 C NMR (151MHz, CDCl3-d6) δ173.20,161.94,159.52,158.07,144.35,137.12,134.86,134.36,129.30,127.77,126.26,121.84,121.03,120. 37,113.58,110.55,109.76,107.95,104.66,57.49,57.23,56.11,55.79,45.29,44.32,42.54,32.54,31.26,10.90.HRMS(EI)(m / z):calcd for C 30 H 39 N7O3[M] + 545.3114, found 545.3111.
[0152] Synthesis of N1-(3-methoxy-4-nitrophenyl)-N1,N2,N2-trimethylethane-1,2-diamine (2g) (step f)
[0153]
[0154] 2f (425.00 mg, 2.5 mmol) was dissolved in 5 mL of N, N-dimethylformamide, and N, N, N'-trimethylethylenediamine (380.00 mg, 3.72 mmol) and potassium carbonate (750.00 mg, 4.9 mmol) were added thereto in sequence. The reaction was carried out at 110°C for 3 h and monitored by TLC. After the reaction was completed, the mixture was cooled to room temperature, water was added, and the mixture was extracted with ethyl acetate. The organic phase was collected, dried over anhydrous sodium sulfate, filtered, and the filtrate was spin-dried and separated by silica gel column chromatography with dichloromethane: methanol = 100: 1 to obtain 2 g of yellow-green liquid (370 mg), with a yield of 60%.
[0155] 1 H NMR (400MHz, Chloroform-d): δ8.00–7.86(m,1H),6.17(ddd,J=9.5,6.8,2.4Hz,1H),6.11–6.00(m,1H),3.89(dd,J= 5.8, 1.8Hz, 3H), 3.48 (q, J = 6.8Hz, 2H), 3.09–2.98 (m, 3H), 2.45 (dt, J = 10.3, 6.4Hz, 2H), 2.24 (dd, J = 5.6, 1.8Hz, 6H). LC-MS:m / z:254.3(M+H) + .
[0156] Synthesis of N1-(3-methoxy-4-aminophenyl)-N1,N2,N2-trimethylethane-1,2-diamine (2h) (step g)
[0157]
[0158] Put 2g (250.00mg, 1.0mmol) into a 50mL three-necked flask, add 10mL of methanol, add palladium carbon (50.00mg, 20%) after dissolution, replace with hydrogen three times, react at 25°C for 5h, filter with diatomaceous earth, collect the filtrate, spin dry, and use it directly in the next reaction.
[0159] Example 4: Synthesis of 3-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)pyrimidin-4-yl)-1H-indol-1-yl)propan-1-ol (4)
[0160]
[0161] Green solid, yield 14%.
[0162] 1H NMR (400MHz, Chloroform-d): δ8.30–8.25(m,1H),8.23–8.17(m,2H),7.84(s,1H),7.38–7 .31(m,1H),7.25(s,1H),7.22–7.13(m,3H),6.91(d,J=5.3Hz,1H),6.38(dd,J=8.8,2.7Hz, 1H),6.32(d,J=2.7Hz,1H),4.27(t,J=6.7Hz,2H),3.80(s,3H),3.54(t,J=5.8Hz,2H),3.4 7(t,J=7.4Hz,2H),2.87(s,3H),2.63(t,J=7.3Hz,2H),2.39(s,6H),2.01(p,J=6.4Hz,2H). 13 C NMR (151MHz, DMSO-d6): δ162.59,161.61,157.33,152.88,146.91,146.10,138.16,132.17,126.23,125.98,123.18,122.52,121.02,1 19.12,113.22,110.77,106.71,104.46,97.44,58.15,55.92,54.72,49.35,44.68,43.46,39.07,33.18,21.26.HRMS(EI)(m / z):calcd for C 27 H 34 N6O2[M] + 474.2743, found 474.2745.
[0163] Synthesis of 7-vinyl-1H-indole (2k)
[0164]
[0165] Methyltriphenylphosphine iodide (1.30 g, 3.2 mmol) was placed in a 100 mL three-necked flask, and the atmosphere was replaced with nitrogen three times. 10 mL of anhydrous tetrahydrofuran was added. A mixture of potassium bis(trimethylsilyl)amide (3.22 mL, 3.2 mmol) and 10 mL of anhydrous tetrahydrofuran was added dropwise into the three-necked flask through a constant pressure dropping funnel. The mixture was reacted at 25° C. for 1 h. 2j (188.00 mg, 1.3 mmol) was added and reacted at 25° C. for 2 h. The reaction was stopped by TLC monitoring, quenched with a saturated ammonium chloride solution, extracted with water and ethyl acetate, dried over anhydrous sodium sulfate, filtered, and the filtrate was spin-dried and chromatographed on a silica gel column. The mixture was separated with petroleum ether:ethyl acetate=15:1 to obtain 171 mg of a light green liquid intermediate with a yield of 90%. Under ice bath, the intermediate was put into a 100mL three-necked flask, 10mL of anhydrous tetrahydrofuran was added and mixed, nitrogen was replaced three times, borane tetrahydrofuran (5mL, 5.0mmol) was added dropwise, and after the addition was complete, the temperature was restored to room temperature and the reaction was carried out for 1h. Then, sodium hydroxide solution (10mL, 1mol / L) and hydrogen peroxide (10mL, 30%) were slowly added dropwise, and the reaction was refluxed for 1h. After TLC monitoring, the reaction was completed, the mixture was cooled to room temperature and 15mL of saturated sodium sulfite solution was added, and the mixture was extracted with ethyl acetate. The organic phase was collected, dried over anhydrous sodium sulfate, and filtered. The filtrate was separated by silica gel column chromatography with petroleum ether: ethyl acetate = 20:1 to obtain 38mg of 2k as a light green liquid with a yield of 20%.
[0166] 1 H NMR (400MHz, Chloroform-d): δ8.91(s,1H),7.46(d,J=7.8Hz,1H),7.09(t,J=2.8Hz,1H),6.98(t,J=7.5Hz,1H),6.8 9(d,J=7.0Hz,1H),6.47(dd,J=3.2,2.0Hz,1H),3.87(t,J=5.8Hz,2H),2.98(t,J=5.7Hz,2H).LC-MS:m / z:162.2(M+H) + .
[0167] Example 5: Synthesis of 2-(3-(2-((4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)ethanol (10)
[0168]
[0169] Compound 10 was obtained by referring to the synthetic route of compound 4. Pale yellow solid, yield 23%.
[0170] 1H NMR (400MHz, DMSO-d6): δ11.69(d,J=3.0Hz,1H),8.24(d,J=6.7Hz,1H),8.21(d,J=3.0Hz,1H),8.18 (d,J=5.3Hz,1H),7.78(s,1H),7.63(d,J=8.7Hz,1H),7.15(d,J=5.3Hz,1H),6.99(q,J=4.2Hz,2H),6 .42(d,J=2.6Hz,1H),6.32(dd,J=8.8,2.6Hz,1H),4.71(t,J=5.1Hz,1H),3.80(s,3H),3.71(td,J=7 .0,4.8Hz,2H),3.49(t,J=7.2Hz,2H),3.03(t,J=7.0Hz,2H),2.94(s,3H),2.57(s,2H),2.32(s,6H). 13 C NMR (151MHz, DMSO-d6): δ167.54,164.71,156.53,153.88,147.54,144.32,139.21,134.32,127.63,126.32,122.78,122.62,12 0.32,119.54,113.73,110.81,106.82,103.86,97.74,60.25,55.52,54.42,49.43,44.78,43.46,33.32.HRMS(EI)(m / z):calcd for C 26 H 32 N6O2[M] + 460.2587,found460.2581.
[0171] Example 6: Synthesis of N-(2-fluoro-5-((4-(6-fluoro-1-(3-hydroxypropyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)propanamide (5)
[0172]
[0173] Compound 5 was obtained by referring to the synthetic route of compound 1. Yellow solid, yield 21%.
[0174] 1H NMR (400MHz, DMSO-d6): δ9.54(s,1H),8.45(s,1H),8.33(dd,J=21.5,6.9Hz,3H), 8.17(s,1H),7.46(dd,J=10.2,2.4Hz,1H),7.23(d,J=5.5Hz,1H),7.09(d,J=12.1 Hz,1H),6.99(td,J=9.2,2.3Hz,1H),4.30(t,J=6.9Hz,2H),3.85(s,3H),3.41(t, J=6.1Hz,2H),2.35(q,J=7.5Hz,2H),1.96(p,J=6.6Hz,2H),1.07(t,J=7.6Hz,3H). 13 C NMR (151MHz, DMSO): δ172.50,162.42,160.42,158.85,152.08,150.45,148.58,137.74,133.58,124.70,123.93,122.68, 119.81,118.12,113.25,109.64,107.61,100.35,97.58,58.09,56.79,43.67,33.09,29.24,10.13.HRMS(EI)(m / z):calcd for C 25 H 25 F2N5O3[M] + 481.1925, found 481.1927.
[0175] Synthesis of 2-(1H-indol-1-yl)ethanol (2l)
[0176]
[0177] 2-Bromoethanol (230.00 mg, 1.8 mmol) was placed in a 25 mL single-necked bottle, and 4 mL of dichloromethane was added to dissolve it. Subsequently, tert-butyldimethylsilyl chloride (300.00 mg, 2.0 mmol) and imidazole (140.00 mg, 2.0 mmol) were added in sequence. The reaction was carried out at 25 °C for 3 h, and the mixture was filtered off with suction, washed with dichloromethane, and the filtrate was collected and dried to obtain the intermediate. 2a (108.00 mg, 0.9 mmol) and sodium hydride (72.00 mg, 1.8 mmol) were weighed and placed in a 50 mL two-necked bottle. The atmosphere was replaced with nitrogen three times. Under an ice bath, 7 mL of anhydrous N,N-dimethylformamide solution was slowly added. After stirring for 15 min, the intermediate was added, and the temperature was raised to 100 °C for reaction for 4 h. The reaction was monitored by TLC. After the reaction was completed, the mixture was cooled to room temperature, quenched with water, and extracted with dichloromethane. The organic phase was collected, dried over anhydrous sodium sulfate, and dried to obtain 230 mg of 2l yellow liquid. The yield was 80%.
[0178] 1 H NMR (400MHz, Chloroform-d): δ7.55(d,J=7.9Hz,1H),7.29(d,J=8.2Hz,1H),7.16–7.09(m,1H),7.06–6. 97(m,2H),6.41(d,J=3.1Hz,1H),4.09(t,J=6.7Hz,2H),3.50(t,J=6.0Hz,2H),.LC-MS:m / z:162.2(M+H) + .
[0179] Example 7: Synthesis of N-(2-fluoro-5-((4-(1-(2-hydroxyethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)propanamide (6)
[0180]
[0181] Compound 6 was obtained by referring to the synthetic route of compound 1. White solid, yield 23%.
[0182] 1 H NMR (400MHz, DMSO-d6): δ9.51 (s, 1H), 8.48 (d, J = 8.4Hz, 1H), 8.42 (s, 1H), 8.32 (dd, J=13.6,6.7Hz,2H),7.97(s,1H),7.57(d,J=8.1Hz,1H),7.22(t,J=6.2Hz,2H),7.15 (t,J=7.5Hz,1H),7.07(d,J=12.0Hz,1H),4.96(t,J=5.1Hz,1H),4.32(t,J=5.5Hz,2 H), 3.86 (s, 3H), 3.79 (q, J = 5.4Hz, 2H), 2.36 (q, J = 7.5Hz, 2H), 1.07 (t, J = 7.5Hz, 3H). 13 C NMR (151MHz, DMSO): δ172.48,172.45,162.52,160.49,157.72,151.66,150.06,147.97,147.90,137.73,133.47,126.04,125.08,122.40 ,121.25,118.94,118.09,118.00,112.86,111.19,107.80,100.21,100.05,60.44,56.81,49.25,29.25,10.16.HRMS(EI)(m / z):calcdfor C 24 H24 FN5O3[M] + 449.1863, found 449.1862.
[0183] Example 8: Synthesis of N-(2-fluoro-5-((4-(1-(4-hydroxybutyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)propanamide (7)
[0184]
[0185] Compound 7 was obtained by referring to the synthetic route of compound 1. It was a yellowish brown solid with a yield of 10%.
[0186] 1 H NMR (400MHz, DMSO-d6): δ9.54(s,1H),8.52(s,1H),8.48(d,J=8.6Hz,1H),8.31(t,J= 7.3Hz,2H),8.13(s,1H),7.58(d,J=8.2Hz,1H),7.28–7.21(m,2H),7.16(t,J=7.5Hz, 1H),7.08(d,J=12.2Hz,1H),4.30(t,J=7.0Hz,2H),3.86(s,3H),3.41(t,J=6.4Hz,2H ),2.37(q,J=7.6Hz,2H),1.92–1.79(m,2H),1.51–1.35(m,2H),1.08(t,J=7.6Hz,3H). 13 C NMR (151MHz, DMSO): δ172.52,137.54,126.01,122.79,122.52,121.61,112.83,111.21,107. 61,100.44,100.27,60.71,56.84,46.54,30.14,29.29,26.88,10.18.HRMS(EI)(m / z):calcd for C 26 H 28 FN5O3[M] + 477.2176, found 477.2179.
[0187] Synthesis of 1H-Indole-2-carboxaldehyde (2n)
[0188]
[0189] Under ice bath, 2m (806.00mg, 5.0mmol) was loaded into 100mL three-necked flask, 30mL anhydrous tetrahydrofuran was added to dissolve, and lithium aluminum tetrahydride (380.00mg, 10.0mmol) was added in batches while stirring, and the mixture was restored to room temperature after addition, and the reaction was carried out for 14h. After the reaction was completed, the mixture was quenched with saturated ammonium chloride solution, filtered by suction, and the filtrate was collected and extracted with ethyl acetate, dried over anhydrous sodium sulfate, and the solvent was spin-dried to obtain an intermediate. The intermediate was dissolved in 10mL dimethyl sulfoxide, 2-iodylbenzoic acid (1.70g, 6.0mmol) was added, and the mixture was reacted at 25°C for 10h, monitored by TLC, and a large amount of water was added to the reaction and extracted with ethyl acetate, dried over anhydrous sodium sulfate, and the filtrate was spin-dried for silica gel column chromatography, and separated with petroleum ether: ethyl acetate = 20:1 to obtain 2n as a white solid 650mg, with a yield of 89%.
[0190] 1 H NMR (400MHz, Chloroform-d): δ9.78(s,1H),9.30(s,1H),7.68(d,J=8.0Hz,1H),7.43–7.37(m,1H),7.32( ddd,J=8.2,6.8,1.1Hz,1H),7.23–7.16(m,1H),7.11(ddd,J=8.0,6.9,1.0Hz,1H).LC-MS:m / z:146.1(M+H) + .
[0191] Synthesis of 3-(1H-indol-2-yl)propan-1-ol (2o)
[0192]
[0193] Under ice bath, triethyl phosphoacetate (6.67 g, 29.7 mmol) and sodium hydride (1.5 g, 37.5 mmol) were placed into a 100 mL three-necked flask, 20 mL of anhydrous tetrahydrofuran was slowly added to dissolve, and after stirring for 1 h, a solution of 2n (3.60 g, 24.8 mmol) dissolved in 20 mL of anhydrous tetrahydrofuran was added dropwise through a constant pressure dropping funnel, and the mixture was reacted at 25 ° C for 10 h, monitored by TLC, and the reaction was terminated by quenching the reaction with saturated ammonium chloride solution, the solvent was spin-dried, extracted with water and ethyl acetate, dried over anhydrous sodium sulfate, and the filtrate was spin-dried to obtain an intermediate. Under ice bath, lithium aluminum tetrahydride (2.00 g, 52.6 mmol) was slowly added to 30 mL of anhydrous tetrahydrofuran solution, and then the intermediate solution dissolved in 30 mL of anhydrous tetrahydrofuran was slowly added thereto, and the reaction was carried out at 20 ° C for 8 h. After monitoring by TLC, the reaction was terminated, and water was added to quench the reaction, and the mixture was extracted with ethyl acetate and dried over anhydrous sodium sulfate. The filtrate was spin-dried and subjected to silica gel column chromatography. 2.58 g of 2o as a white solid was separated using petroleum ether: ethyl acetate = 8:1, and the yield was 60%.
[0194] 1 H NMR (400MHz, Chloroform-d): δ8.15(s,1H),7.44(dd,J=7.2,1.6Hz,1H),7.20–7.13(m,1H),7.00(dtd,J=16.2,7.2,1.3Hz ,2H),6.16–6.09(m,1H),3.57(t,J=6.1Hz,2H),2.70(t,J=7.3Hz,2H),1.81(tt,J=7.3,6.1Hz,2H).LC-MS:m / z:176.2(M+H) + .
[0195] Example 9: Synthesis of N-(2-fluoro-5-((4-(2-(3-hydroxypropyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)propanamide (8)
[0196]
[0197] Compound 8 was obtained by referring to the synthetic route of compound 1. Yellow-brown solid, yield 23%.
[0198] 1 H NMR (400MHz, DMSO-d6): δ11.56(s,1H),9.45(s,1H),8.36(d,J=5.3Hz,1H),8 .29(d,J=8.5Hz,1H),8.07–7.94(m,2H),7.36(d,J=7.9Hz,1H),7.14–7.01(m, 4H), 4.60 (d, J = 5.2Hz, 1H), 3.85 (s, 3H), 3.44 (q, J = 5.6Hz, 2H), 3.11 (t, J = 7. 8Hz, 2H), 2.31 (q, J = 7.5Hz, 2H), 1.85 (p, J = 6.7Hz, 2H), 1.05 (t, J = 7.5Hz, 3H). 13 CNMR (151MHz, DMSO): δ172.41,163.18,160.64,157.83,143.57,135.84,126.99,125.08,121.73,120.60,11 9.76,111.56,110.31,109.85,100.17,60.76,56.82,32.64,29.12,24.61,10.17.HRMS(EI)(m / z):calcdfor C 25 H 26 FN5O3[M] +463.2020, found 463.2023.
[0199] Example 10: Synthesis of N-(2-fluoro-5-((4-(7-(2-hydroxyethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)-4-methoxyphenyl)propanamide (9)
[0200]
[0201] Compound 9 was obtained by referring to the synthetic route of compound 1. Light yellow solid, yield 22%.
[0202] 1 H NMR (400MHz, DMSO-d6): δ11.73(d,J=3.0Hz,1H),9.50(s,1H),8.36(d,J=8.6Hz,1H) ,8.30(d,J=3.0Hz,1H),8.27(d,J=5.4Hz,1H),8.25–8.19(m,1H),7.99(s,1H),7.29( d,J=5.4Hz,1H),7.10–6.97(m,3H),4.71(t,J=5.0Hz,1H),3.85(s,3H),3.72(td,J= 7.0,4.7Hz,2H),3.04(t,J=7.0Hz,2H),2.33(q,J=7.6Hz,2H),1.06(t,J=7.5Hz,3H). 13 C NMR (151MHz, DMSO): δ172.48,172.45,162.52,160.49,157.72,151.66,150.06,147.97,148.91,137.73,133.47,126.04,125.08,122. 40,121.25,118.95,118.06,118.00,112.86,112.19,107.80,100.21,99.05,60.44,56.81,49.25,29.25,10.16.HRMS(EI)(m / z):calcd for C 24 H 24 FN5O3[M] + 449.1863, found 449.1862.
[0203] Example 11: Synthesis of N-(2-fluoro-5-((6-(6-fluoro-1-(3-hydroxypropyl)-1H-indol-3-yl)pyrimidin-4-yl)amino)-4-methoxyphenyl)propanamide (16)
[0204]
[0205] Compound 16 was obtained by referring to the synthetic route of compound 1. White solid, yield 30%.
[0206] 1 H NMR (400MHz, DMSO-d6): δ9.53(s,1H),8.72(s,1H),8.54(d,J=1.0Hz,1H),8.31(d d,J=8.9,5.6Hz,1H),8.26(d,J=8.5Hz,1H),8.15(s,1H),7.47(dd,J=10.2,2.4Hz, 1H),7.29(s,1H),7.12–6.98(m,2H),4.67(t,J=5.0Hz,1H),4.29(t,J=6.8Hz,2H) ,3.87(s,3H),2.35(q,J=7.5Hz,2H),1.92(q,J=6.5Hz,2H),1.08(t,J=7.6Hz,3H). 13 C NMR (151MHz, DMSO): δ172.59,161.36,158.75,158.30,137.65,131.87,124.23,122.90,122.51,120.49,117. 99,113.68,109.42,109.27,100.36,97.58,58.04,56.80,43.43,33.03,29.15,10.18.HRMS(EI)(m / z):calcd for C 25 H 25 F2N5O3[M] + 481.1925, found 481.1927.
[0207] Synthesis scheme of trisubstituted imidazoles
[0208]
[0209] The reaction reagents and conditions of each step are as follows:
[0210] (h)SeO2,1,4-dioxane,H2O,100℃,overnight;
[0211] (i) HCl, H2O, 25°C, 5h;
[0212] (j) NH4OAc, MeOH, 25℃, overnight, 6%;
[0213] (k) Pd / C, H2, MeOH, 25℃, 6h, 69%;
[0214] (l) 2-(1-oxoisoindolin-2-yl)-2-phenylacetic acid, HATU, DIPEA, DMF, 25°C, 6h, 5%;
[0215] (m) NIS, MeCN, 80℃, 16h, 30%;
[0216] (n)1,4-dioxane,K2CO3,H2O,Pd(dppf)Cl2·CH2Cl2,N-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine, 90℃, 12h, 32%.
[0217] Synthesis of 3-(4-(4-nitrophenyl)-1H-imidazol-2-yl)propan-1-ol (2t) (step j)
[0218]
[0219] Selenium dioxide (5.36 g, 48.7 mmol) was placed in a 250 mL three-necked flask, 60 mL of 1,4-dioxane and 20 mL of water were added, stirred and dissolved at 55 ° C, and 2p (2.00 g, 12.1 mmol) was added after complete dissolution, the temperature was raised to 100 ° C, the reaction was continued for 10 h, the reaction was terminated and cooled to room temperature, filtered with suction, and diatomaceous earth was used to assist the filtration, the filtrate was collected and extracted with ethyl acetate, dried over anhydrous sodium sulfate, and the filtrate was spin-dried and subjected to silica gel column chromatography to obtain intermediate 2q. Under ice bath, hydrochloric acid (14 mL, 2 mol / L) was weighed and placed in a 50 mL three-necked flask, 2r (1.40 g, 20.0 mmol) was added dropwise, stirred for 0.5 h, returned to room temperature and continued to react for 5 h, TLC detection, the reaction was terminated and extracted with dichloromethane, the organic phase was collected, and the solvent was spin-dried to obtain intermediate 2s. 2s and ammonium acetate (4.90 g, 63.6 mmol) were sequentially placed in a 250 mL single-necked bottle, and 30 mL of methanol was added to dissolve it. 2p was dissolved in 60 mL of methanol and added dropwise to the single-necked bottle. The reaction was allowed to proceed overnight at 25°C and detected by TLC. After the reaction was completed, the solvent was concentrated and the pH value was adjusted to 7 with saturated sodium bicarbonate. Ethyl acetate was added to extract, the mixture was dried over anhydrous sodium sulfate, and the mixture was filtered. The filtrate was separated by silica gel column chromatography with dichloromethane:methanol=150:1 to obtain 2t, a yellow liquid (260 mg), with a yield of 6%.
[0220] 1H NMR (400MHz, DMSO-d6): δ8.25–8.17(m,2H),8.02–7.94(m,2H),7.81(s,1H),3.48(t,J=6.3 Hz,2H),2.72(dd,J=8.2,7.1Hz,2H),1.85(dq,J=8.1,6.4Hz,2H)..LC-MS:m / z:248.1(M+H) + .
[0221] Synthesis of 3-(4-(4-aminophenyl)-1H-imidazol-2-yl)propan-1-ol (2u) (step k)
[0222]
[0223] 2t (184.00 mg, 0.8 mmol), palladium carbon (40.00 mg, 20%) and 12 mL of methanol were sequentially charged into a 100 ml single-mouth bottle and replaced with hydrogen three times. The reaction was carried out at 25 ° C for 6 h and monitored by TLC. The reaction was terminated and filtered with diatomaceous earth. The filtrate was separated by silica gel column chromatography with dichloromethane: methanol = 40:1 to obtain 112 mg of 2u as an orange-yellow liquid, with a yield of 69%.
[0224] 1 H NMR (400MHz, DMSO-d6): δ7.39–7.31(m,2H),7.09(s,1H),6.60–6.51(m,2H),3.47( t,J=6.3Hz,2H),2.67(t,J=7.6Hz,2H),1.89–1.73(m,2H).LC-MS(m / z):218.1(M+H) + .
[0225] Synthesis of 2-(1-oxoisoindolin-2-yl)-2-phenylacetic acid (2w)
[0226]
[0227] Place o-phthalaldehyde (1.00 g, 7.5 mmol) into a 250 mL single-mouth bottle, dissolve it with 35 mL of acetonitrile, add D, L-phenylglycine (1.13 g, 7.5 mmol) and 2 mL of acetic acid, replace with nitrogen three times, reflux for 3 h, monitor by TLC, and after the reaction is completed, filter, wash the filter cake and vacuum dry to obtain 1.3 g of 2w black solid, with a yield of 65%. 1H NMR (400MHz, DMSO-d6): δ13.39(s,1H),7.75(d,J=7.5Hz,1H),7.60(td,J=7.4,1.2Hz,1H),7.57–7.49(m,2 H),7.50–7.37(m,5H),6.00(s,1H),4.64(d,J=17.4Hz,1H),3.92(d,J=17.4Hz,1H).LC-MS:m / z:268.1(M+H) + .
[0228] Example 12: Synthesis of N-(3-(2-(3-hydroxypropyl)-1H-imidazol-4-yl)phenyl)-2-(1-oxoisoindolin-2-yl)-2-phenylacetamide (11)
[0229]
[0230] 2u (176.00 mg, 0.8 mmol), 2w (108.00 mg, 0.4 mmol) and 2-(7-benzotriazole oxide)-N,N,N',N'-tetramethyluronium hexafluorophosphate (308.00 mg, 0.8 mmol) were placed in a 25 mL single-mouth bottle, 2.5 mL of N,N-dimethylformamide was added to dissolve, N,N-diisopropylethylamine (212.00 mg, 1.6 mmol) was added under stirring, and the reaction was carried out at 25 ° C for 6 h, monitored by TLC. After the reaction was completed, it was extracted with water and ethyl acetate, the organic phase was collected, dried over anhydrous sodium sulfate, and filtered. The filtrate was separated by silica gel column chromatography with dichloromethane: methanol = 200: 1 to obtain 11 as a white solid 20 mg, yield 5%.
[0231] 1 H NMR (400MHz, DMSO-d6): δ10.57(s,1H),8.01(d,J=1.8Hz,1H),7.76(d,J=7.5Hz,1H),7.65–7.35(m,12H),7.29(t,J=7.9Hz,1H), 6.24(s,1H),4.85(d,J=17.7Hz,1H),3.97(d,J=17.6Hz,1H),3.45(t,J=6.3Hz,2H),2.70(t,J=7.6Hz,2H),1.82(p,J=6.8Hz,2H). 13C NMR (151MHz, DMSO): δ168.63,168.18,149.08,142.88,139.32,135.93,132.16,132.00,129.49,129.08,128.9 3,128.43,124.12,123.41,120.28,117.77,115.72,60.62,59.02,48.90,31.58,24.94.HRMS(ESI)(m / z):calcd for C 39 H 34 N6O3[M+H] + 467.2083, found 467.2084.
[0232] Example 13: Synthesis of N-(4-(2-(3-hydroxypropyl)-1H-imidazol-4-yl)phenyl)-2-(1-oxoisoindolin-2-yl)-2-phenylacetamide (12)
[0233]
[0234] Compound 12 was obtained by referring to the synthetic route of compound 11. It was a yellowish brown solid with a yield of 8%.
[0235] 1 H NMR (400MHz, DMSO-d6): δ10.55(s,1H),7.76(d,J=7.5Hz,1H),7.70–7.55(m,6H),7.54–7.37(m,7H),6.24(s,1H),4 .85(d,J=17.7Hz,1H),3.98(d,J=17.7Hz,1H),3.46(t,J=6.3Hz,2H),2.70(t,J=7.6Hz,2H),1.83(p,J=6.6Hz,2H). 13 C NMR (151MHz, DMSO) δ168.74,168.23,150.06,148.90,147.73,142.88,138.65,135.71,133.80,132.21,131.94,129.56,129.05,12 8.46,127.57,126.69,125.79,124.14,123.41,120.11,114.30,112.01,60.23,59.05,48.89,30.85,23.80.HRMS(ESI)(m / z):calcd for C 39 H 34 N6O3[M+H] +467.2083, found 467.2084.
[0236] Synthesis of 3-chloro-N-phenylpyridin-2-amine (2x)
[0237]
[0238] Palladium acetate (13.5 mg, 0.1 mmol) and 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl (37.5 mg, 0.1 mmol) were placed in a 50 mL single-mouth bottle, replaced with nitrogen three times, dissolved with 10 mL of toluene, stirred at 25°C for 10 min, and then the solution was transferred to a solution containing 2,3-dichloropyridine (441.00 mg, 3.0 mmol), aniline (329.00 uL, 3.6 mmol), potassium carbonate (8.30 g, 60.0 mmol) and 17 mL of toluene, replaced with nitrogen three times, refluxed for 4 h, monitored by TLC, and cooled to room temperature after the reaction was completed. Celite was used as the filter aid, and the filtrate was extracted with dichloromethane, dried over anhydrous sodium sulfate, filtered, and the filtrate was collected. The filtrate was spin-dried and subjected to silica gel column chromatography, separated with petroleum ether: ethyl acetate = 100:1 to obtain 2x light orange liquid 267 mg, with a yield of 43%.
[0239] 1 H NMR (400MHz, Chloroform-d): δ8.03(dd,J=4.8,1.7Hz,1H),7.57–7.51(m,2H),7.46(dd,J=7.7,1.7Hz,1H ),7.29–7.22(m,2H),7.00–6.93(m,1H),6.90(s,1H),6.60(dd,J=7.7,4.8Hz,1H).LC-MS:m / z:205.1(M+H) + .
[0240] Synthesis of N-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (2y)
[0241]
[0242] Tris(dibenzylideneacetone)dipalladium (12.00 mg, 0.013 mmol), biboric acid pinacol ester (1.00 g, 3.9 mmol), 2-dicyclohexylphospho-2,4,6-triisopropylbiphenyl (13.00 mg, 0.026 mmol) and potassium acetate (385.00 mg, 3.9 mmol) were placed in a 50 mL three-necked flask, and the atmosphere was replaced with nitrogen three times. 2x (267.00 mg, 1.3 mmol) was weighed and dissolved in 8 mL of anhydrous 1,4-dioxane, and added to the three-necked flask. The mixture was reacted at 110 ° C. for 16 h and monitored by TLC. After the reaction was completed, the mixture was cooled to room temperature and filtered with suction. The filtrate was filtered with diatomaceous earth as the aid of filtration. The filtrate was extracted with ethyl acetate and dried over anhydrous sodium sulfate. The filtrate was spin-dried and subjected to silica gel column chromatography. It was separated with petroleum ether: ethyl acetate = 20:1 to obtain 2y, a light orange liquid, which was directly used in the next step of the reaction.
[0243] Synthesis of N-(3-(2-(3-hydroxypropyl)-5-iodo-1H-imidazol-4-yl)phenyl)-2-(1-oxoisoindolin-2-yl)-2-phenylacetamide (2v) (Step m)
[0244]
[0245] 11 (104.00 mg, 0.2 mmol) was placed in a 25 mL single-mouth bottle, 6 mL of acetonitrile was added to dissolve, N-iodosuccinimide (61.00 mg, 0.3 mmol) was added in batches with stirring, the temperature was raised to 80°C, the reaction was allowed to react for 16 h, and the reaction was stopped after TLC monitoring. The mixture was cooled to room temperature, extracted with ethyl acetate, dried over anhydrous sodium sulfate, and the filtrate was spin-dried and purified by silica gel column chromatography. The mixture was separated with dichloromethane:methanol=100:1 to obtain 40 mg of 2v as a light yellow solid with a yield of 30%.
[0246] 1 H NMR (400MHz, DMSO-d6): δ10.51(s,1H),8.11(d,J=1.8Hz,1H),7.76(d,J=7.5Hz,1H),7.65–7.35(m,11H),7.29(t,J=7.9Hz,1H),6.25(s,1H) ,4.82(d,J=17.7Hz,1H),3.82(d,J=17.6Hz,1H),3.41(t,J=6.3Hz,2H),2.81(t,J=7.6Hz,2H),1.91(p,J=6.8Hz,2H).LC-MS:m / z:593.1(M+H) + .
[0247] Example 14: Synthesis of N-(3-(2-(3-hydroxypropyl)-5-(2-(phenylamino)pyridin-3-yl)-1H-imidazol-4-yl)phenyl)-2-(1-oxoisoindolin-2-yl)-2-phenylacetamide (13)
[0248]
[0249] Potassium carbonate (24.00 mg, 0.2 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex (6.00 mg, 0.007 mmol) were sequentially placed in a 25 mL three-necked flask, and the atmosphere was replaced with nitrogen three times. A solution of 2v and 2y dissolved in 4 mL of 1,4-dioxane and 1 mL of water was added, and the mixture was reacted at 90° C. for 14 h and monitored by TLC. After the reaction was completed, the mixture was cooled to room temperature and extracted with ethyl acetate, dried over anhydrous sodium sulfate, and filtered. The organic phase was collected and the filtrate was spin-dried and separated by silica gel column chromatography with dichloromethane:methanol=100:1 to obtain 14 mg of 13 as a white solid with a yield of 32%.
[0250] 1 H NMR (400MHz, Chloroform-d): δ9.95 (s, 1H), 8.98 (s, 1H), 8.03 (d, J = 4.8Hz, 1 H),7.69(d,J=7.6Hz,1H),7.61–7.32(m,11H),7.24–7.10(m,3H),6.97–6.73( m,3H),6.49(s,1H),6.44(q,J=7.1,6.5Hz,1H),4.86(d,J=17.5Hz,1H),4.00 (d,J=17.5Hz,1H),3.56(t,J=5.5Hz,2H),2.83(d,J=7.0Hz,2H),1.91(s,2H). 13 CNMR (151MHz, DMSO): δ168.54,168.31,154.02,149.33,144.23,143.29,141 .73,139.49,135.23,132.71,132.11,131.84,129.37,129.17,129.07,129.0 1,128.85,128.31,128.10,126.36,124.35,124.11,120.72,120.33,118.34 ,116.37,114.64,60.24,59.34,48.69,31.70,23.87.HRMS(ESI)(m / z):calcd for C 39 H 34 N6O3[M+H] +635.2771, found 635.2772.
[0251] Example 15: Synthesis of N-(4-(2-(3-hydroxypropyl)-5-(2-(phenylamino)pyridin-3-yl)-1H-imidazol-4-yl)phenyl)-2-(1-oxoisoindolin-2-yl)-2-phenylacetamide (14)
[0252]
[0253] Compound 14 was obtained by referring to the synthetic route of compound 13. White solid, yield 25%.
[0254] 1 H NMR (400MHz, DMSO-d6): δ12.41(s,1H),10.72(s,1H),10.66(s,1H),8.05(dd,J=4.8,1.9Hz,1H),7.76(d,J=7. 6Hz,1H),7.68(dd,J=15.3,8.2Hz,3H),7.63–7.54(m,2H),7.54–7.40(m,5H),7.36(dd,J=8.4,2.0Hz,3H),7.28 (t,J=7.7Hz,2H),6.89(t,J=7.4Hz,1H),6.62(dd,J=7.5,4.9Hz,1H),6.23(s,1H),4.83(d,J=17.7Hz,1H),4.6 1(t,J=5.1Hz,1H),3.98(d,J=17.7Hz,1H),3.56(q,J=6.0Hz,2H),2.82(t,J=7.6Hz,2H),1.97(p,J=6.9Hz,2H). 13 C NMR (151MHz, DMSO): δ168.74,168.21,153.08,148.23,145.73,142.89,141. 89,138.39,135.73,132.20,132.01,131.94,129.57,129.17,129.08,129.0 2,128.95,128.46,128.00,126.66,124.16,123.41,120.88,120.00,118.60 ,115.27,114.34,60.60,59.04,48.89,31.40,24.77.HRMS(ESI)(m / z):calcd for C 39 H 34 N6O3[M+H] + 635.2771, found 635.2772.
[0255] Synthesis of N-phenyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-amine (2z)
[0256]
[0257] [1,1′-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex (31.00 mg, 0.04 mmol), bipyraclostrobin (480.00 mg, 2.0 mmol), 4-bromo-7-azaindole (184.00 mg, 1.0 mmol) and potassium acetate (240.00 mg, 3.0 mmol) were sequentially placed into a 25 mL three-necked flask, the atmosphere was replaced with nitrogen three times, anhydrous 1,4-dioxane was added, the reaction was carried out at 90° C. for 18 h, monitored by TLC, the reaction was stopped, cooled to room temperature, filtered, filtered with diatomaceous earth, extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered, and the filtrate was spin-dried to obtain 2z which was directly used in the next step of the reaction.
[0258] Example 16: Synthesis of N-(3-(2-(3-hydroxypropyl)-5-(2-(phenylamino)pyridin-3-yl)-1H-imidazol-4-yl)phenyl)-2-(1-oxoisoindolin-2-yl)-2-phenylacetamide (15)
[0259]
[0260] Potassium carbonate (59.00 mg, 0.4 mmol) and [1,1′-bis(diphenylphosphino)ferrocene]palladium dichloride dichloromethane complex (14.00 mg, 0.017 mmol) were sequentially placed in a 25 mL three-necked flask, and the atmosphere was replaced with nitrogen three times. A solution of 2v and 2z dissolved in 5 mL of 1,4-dioxane and 1.25 mL of water was added, and the mixture was reacted at 90° C. for 12 h and monitored by TLC. After the reaction was completed, the mixture was cooled to room temperature and extracted with ethyl acetate, dried over anhydrous sodium sulfate, filtered, and the filtrate was spin-dried and separated by silica gel column chromatography with dichloromethane:methanol=100:1 to obtain 15 as a white solid (10 mg) with a yield of 10%.
[0261] 1H NMR (400MHz, Chloroform-d): δ9.95 (s, 1H), 8.98 (s, 1H), 8.03 (d, J = 4.8Hz, 1 H),7.69(d,J=7.6Hz,1H),7.61–7.32(m,11H),7.24–7.10(m,3H),6.97–6.73( m,3H),6.49(s,1H),6.44(q,J=7.1,6.5Hz,1H),4.86(d,J=17.5Hz,1H),4.00 (d,J=17.5Hz,1H),3.56(t,J=5.5Hz,2H),2.83(d,J=7.0Hz,2H),1.91(s,2H). 13 CNMR (151MHz, DMSO): δ168.68,168.17,149.57,142.86,139.22,136.37,135.79,132.18,131.93,130.07,129.53,128.97,128.44,1 26.64,124.37,124.13,123.40,118.83,117.59,115.26,100.73,60.53,58.87,48.84,29.48,22.56,14.43.HRMS(ESI)(m / z):calcd for C 39 H 34 N6O3[M+H] + 635.2771, found 635.2772.
[0262] Biological evaluation method:
[0263] Tyrosine kinase: EGFR (WT)
[0264] EGFRT790M / L858R(LR / TM)
[0265] EGFRT790M / L858R / C797S(LR / TM / CS)
[0266] ELISA kinase activity assay
[0267] The ability of kinase to phosphorylate substrates was detected by ELISA, and the inhibitory effect of the compound on kinase activity was calculated. The kinase used was EGFR L858R / T790M / C797S (purchased from BPS Bioscience).
[0268] The main steps of ELISA are as follows: The enzyme reaction substrate Poly (Glu, Tyr) 4:1 was diluted to 2.5 μg / well with potassium-free PBS, and the plate was coated at 37°C for 12-16 hours for standby use. ATP (final concentration 5 μM) solution diluted with reaction buffer (50 mM HEPES pH 7.4, 20 mM MgCl2, 0.1 mM MnCl2, 0.2 mM Na3VO4, 1 mM DTT) was added to each well, and the compound or solvent control was added, and then the kinase was added to start the reaction, and the reaction was shaken at 37°C for 1 hour. The plate was washed three times with T-PBS, and 100 μL of antibody PY99 (T-PBS containing 5 mg / mL BSA, 1:500 dilution) was added and the reaction was shaken at 37°C for 0.5 hours. After washing the plate with T-PBS, add 100 μL of goat anti-mouse IgG labeled with horseradish peroxidase (T-PBS containing 5 mg / mL BSA, 1:2000 dilution) and react on a shaker at 37°C for 0.5 h. After washing the plate again, add 100 μL / well of a colorimetric solution containing 0.03% H2O2 and 2 mg / mL OPD (prepared in 0.1 mol / L, pH 5.4 citrate buffer) and react at 25°C in the dark for 1-10 min. Add 50 μL / well of 2M H2SO4 to terminate the reaction and read with an adjustable wavelength microplate reader (SpectraMax Plus384, Molecular Devices) at a wavelength of 490 nm. The IC50 value is obtained from the inhibition curve.
[0269] The results of enzyme activity test are shown in the following table:
[0270]
[0271]
[0272]
[0273] a Kinase activity assay was performed by using ELISA-based EGFR-TK assay. Data are the average of at least two independent determinations and are expressed as mean ± SD (standard deviation). b Double mutant (EGFR L858R / T790M ). c Triple mutant (EGFR L858R / T790M / C797S ).
[0274]
[0275]
[0276]
[0277] a Kinase activity assay was performed by using ELISA-based EGFR-TK assay. Data are the average of at least two independent determinations and are presented as mean ± SD.
[0278] Cell proliferation inhibition test
[0279] Tyrosine kinase: EGFR T790M / 19DEL / C797S
[0280] Test method: The experiment used the mouse original B cell line BaF3 cell line and EGFR 19del / T790M / C797S -BaF3. At the beginning of the experiment, cells in the logarithmic growth phase were selected, and three groups of cells expressing 19del+T790M+C797S mutations were set up in a 96-well plate. The number of cells in each group was 5000. The highest drug concentration was 10μmol / L, and the concentration was decreased by 1:2. After 72 hours, CCK810ul was added to each well, and the cell activity was measured at 450nm using a thermo microplate reader. Finally, the IC was obtained by fitting the curve. 50 value.
[0281]
[0282]
[0283] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A compound selected from the following or a pharmaceutically acceptable salt thereof:
2. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier or excipient.
3. Use of the compound according to claim 1 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 2, in the preparation of a medicament for treating or preventing EGFR-mediated diseases or inhibiting EGFR.
4. The use according to claim 3, characterized in that The EGFR-mediated disease is cancer.
5. The use according to claim 4, characterized in that The cancer is selected from the following group: non-small cell lung cancer, small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, breast cancer, prostate cancer, glioma, ovarian cancer, head and neck squamous cell carcinoma, cervical cancer, esophageal cancer, liver cancer, kidney cancer, pancreatic cancer, colon cancer, skin cancer, leukemia, lymphoma, gastric cancer, multiple myeloma.
Citation Information
Patent Citations
Methods and compositions for modulating sphingosine-1-phosphate(S1P) receptor activity
CN101018761A
Selectivity inhibitor of EGFR tyrosine kinase clinic important mutant
CN104761544A
Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase
CN109328059A
Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and use thereof
CN1353605A
(substituted phenyl) (substituted pyrimidine) amino derivative, preparation method therefor, and medication use
WO2016029839A1
